AMG553, a second generation anti-FLT3 CAR-T, including a CD28-CD3z CD, showed a good safety profile in an in vivo model and is currently under investigation in a clinical trial in R/R FLT3mut AML (NCT03904069) [47]. This evidence concerns the gene CD247 and acute myeloid leukemia.